Pharmacology of antidepressants: focus on nefazodone

J Clin Psychiatry. 2002:63 Suppl 1:10-7.

Abstract

The past decade has witnessed the introduction of a diverse group of antidepressants from a variety of distinct chemical classes, each with their own specificity for neurochemical transmitters, receptors, and cytochrome P450 isozymes. This review focuses on nefazodone, a distinct antidepressant with efficacy for the treatment of depression with depression-related anxiety symptoms, an established tolerability profile, and a multimodal mechanism of action. Relevant pharmacologic and pharmacodynamic effects are summarized that support nefazodone as an attractive choice for both the short- and long-term treatment of depression.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antidepressive Agents, Second-Generation / pharmacokinetics
  • Antidepressive Agents, Second-Generation / pharmacology*
  • Antidepressive Agents, Second-Generation / therapeutic use
  • Anxiety Disorders / drug therapy
  • Depressive Disorder / drug therapy*
  • Drug Interactions
  • Humans
  • Piperazines
  • Receptors, Serotonin / drug effects
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Serotonin Antagonists / pharmacokinetics
  • Serotonin Antagonists / pharmacology
  • Serotonin Antagonists / therapeutic use
  • Sleep / drug effects
  • Sleep / physiology
  • Triazoles / pharmacokinetics
  • Triazoles / pharmacology*
  • Triazoles / therapeutic use

Substances

  • Antidepressive Agents, Second-Generation
  • Piperazines
  • Receptors, Serotonin
  • Serotonin Antagonists
  • Serotonin Uptake Inhibitors
  • Triazoles
  • nefazodone